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Aim: To analyze patients with Castleman disease who were diagnosed by surgery.
Materials and methods: We retrospectively investigated the postoperative pathological records of operations performed between
January 1992 and December 2012 in our hospital. Files of 19 patients with the diagnosis of Castleman disease were analyzed.
Results: There were 13 male and 6 female patients with a mean age of 40.1 ± 11.4 (range: 20–57) years. Fifteen thoracotomies and 3
video-assisted thoracoscopies, 12 on the right side and 6 on the left side, and 1 mediastinoscopy were performed. Biopsies and mass
excisions were performed in 2 and 17 cases, respectively. Histopathological findings were hyaline vascular-type (n = 16), plasma cellulartype (n = 2), and hyaline vascular plus plasma cellular-type (n = 1) Castleman disease.
Conclusion: Castleman disease can occur in all areas of the thorax, but the mediastinum and hilum are the most common locations.
Surgical excision is the best method of diagnosis and treatment. Complete excision is curative for local forms of the disease. However,
complete excision may not be possible at all times due to local invasion and hypervascularization. Multimodal treatment, including
chemotherapy, is recommended in patients with a multicentric form of the disease, and they should be followed closely.
Key words: Castleman disease, mediastinum, lung, surgery

1. Introduction
Castleman disease (CD) is a benign lymphoid disease
with varying clinical presentations (1). In 1954, Dr
Benjamin Castleman, a pathologist, first described the
rare lymphoproliferative disorder that now bears his name
(2), and in 1956, he reported the first case series (3). CD
is also termed angiofollicular lymph node hyperplasia,
angiomatous lymphoid hyperplasia, Castleman tumor,
giant benign lymphoma, lymph node hamartoma, and
giant lymph node hyperplasia (4). The prevalence of CD
has not been established; it is estimated that this disease
affects fewer than 200,000 people in the United States (1).
It can be observed in various age groups, from adolescence
to individuals in their 70s. It is clinically classified into
localized and multicentric types, and histopathologically
as hyaline vascular, plasma cellular, and mixed types of CD
(4–6).
* Correspondence: piyaren@gmail.com

CD can be observed in any part of the body. It was
reported that 70% of lesions are located in the thorax, 15%
in the neck, and 15% in the abdomen and pelvis (1). In this
study, we present patients with Castleman disease located
in thorax who underwent surgery.
2. Materials and methods
Postoperative pathology results of patients who were
operated on in our surgical department during 1992–2012
were retrospectively examined. Data were analyzed for 19
patients diagnosed with Castleman disease. Demographic
characteristics, clinical presentations, diagnostic methods,
surgical data, histopathological results, postoperative
treatments, prognoses, morbidity, and mortality were
evaluated.
All of the patients underwent chest radiography,
routine blood tests, respiratory function test, and thorax
computed tomography (CT) before surgery.
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3. Results
Of the 19 patients, 13 were male and 6 were female. Mean
age was 40.1 ± 11.4 years (range: 20–57 years). Fourteen
patients were symptomatic, while 5 were asymptomatic
and accidentally diagnosed from chest radiography.
Symptoms included chest pain (n = 8), coughing (n = 3),
shortness of breath (n = 1), shortness of breath combined
with loss of weight (n = 1), and dysphagia and loss of
weight (n = 1). Physical examinations were normal.
Patients’ past histories included bulla ligation surgery
12 years previously, pneumonia 4 years previously, tube
thoracostomy due to pneumothorax 5 months previously,
and prostate carcinoma at the time of diagnosis.
Routine laboratory tests showed hemogram and
biochemistry parameters within normal limits. Lesions
were identified in the pathologic presentation of chest
radiography for all patients. Thorax CT analysis found
solid lesions between 2 and 12 cm (mean: 5.8 cm). Lesions
were located on the mediastinum in 11 cases (3 anterior, 8
posterior mediastinum), the hilum in 7 cases (Figure 1),
and the lungs and mediastinum in 1 case (Figures 2A and
2B). In 1 patient, the left superior pulmonary vein passed
to the mediastinum at the left hilar level and followed a
vertical course. Three-dimensional CT analysis found
that the left superior pulmonary vein poured into the left
brachiocephalic vein. Echocardiography of this patient
with a partial pulmonary venous return abnormality
showed no cardiac pathology. Due to a suspicion of
pulmonary malignancy, abdominal ultrasonography,
brain CT, and bone scintigraphy were conducted in 9
patients, while positron emission tomography (PET)
was done in 4 patients. No extrathoracic pathology was
detected in patients, with the exception of 1 patient who
was examined at another center for prostate cancer; in that
patient, PET showed activity retention in the posterior
mediastinum (standard uptake value max: 3.6) apart from

Figure 1. Thorax CT appearance of the lesion localized in the
right hilar region.
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Figure 2. A) Thorax CT appearance of multicentric plasma
cellular CD that involves the lung and mediastinal lymph nodes
(mediastinum window). B) In the same patient, thorax CT
appearance of bilateral multiple pulmonary lesions (lung window
and different image).

the prostate. The PET of 1 patient showed involvement
in the bilateral lungs as well as the supraclavicular and
mediastinal lymph nodes. A supraclavicular lymph node
biopsy taken from this patient was evaluated as sinusoidal
histiocyte proliferation at a different center. Fiberoptic
bronchoscopy analysis of patients found no bronchial
system pathology other than a narrowing of the upper lobe
bronchus with exterior pressure. Only the patient with
bilateral lung lesions underwent transthoracic fine-needle
biopsy for diagnostic purposes, but it was not diagnostic.
Other patients did not undergo biopsies, as the location of
the lesions was not appropriate. Two patients underwent
endobronchial ultrasonographies, which were not
diagnostic. Two patients had gastroesophagoscopies due
to lesions neighboring the esophagus. Gastroesophageal
reflux was detected in 1 patient, while Barrett’s esophagus
was detected in another. All patients over 40 years of age
were examined by the internal medicine department,
while those over 50 were examined by the cardiology
department and approval was obtained for surgery.
No patients had a preoperative histopathological
diagnosis. Surgery was performed for both diagnosis and
treatment. Fifteen patients underwent thoracotomies (11
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right, 4 left); 3 underwent video-assisted thoracoscopies
(1 right, 2 left). One patient had a mediastinoscopy but,
due to bleeding during the operation, the procedure was
changed to a median sternotomy. Lesions were located
in the posterior mediastinum in 5 patients, in the hilum
in 3 patients, in the anterior mediastinum in 3 patients,
pulmonary in 2 patients, intercostal in 2 patients, lymph
node number 11 in 2 patients, pulmonary and lymph
node number 7 in 1 patient, and multiple lymph nodes
in 1 patient. Three patients underwent pulmonary wedge
resections; 1 of them additionally had a lymphadenectomy;
1 patient had a lymph node biopsy; all other patients had
mass excisions. No additional procedure was performed
since intraoperative frozen pathological analysis showed
that the lesions were not malignant. Complete resection
was achieved in 15 of the patients. However, complete
resection could not be achieved in 2 cases (R2): in 1
patient due to excessive bleeding of lesions and excessive
adherence of lesions to the esophagus wall involving the
posterior mediastinum, and in 1 patient due to the location
of the lesion on the superior and median pulmonary veins.
Two patients had multicentric CD and diagnostic biopsies.
Postoperative histopathological analysis showed that 16 of
the lesions were hyaline vascular (Figure 3), 2 were plasma
cellular (Figures 4A and B), and 1 was hyaline vascular
and plasma cellular mixed-type CD involving lung and
mediastinal lymph nodes.
All patients without postoperative complications
were referred to the oncology clinic. Two patients had
a multicentric and the others had a localized form of
the disease. The human herpes virus 8 (HHV-8) DNA
relationship was analyzed in 3 patients; the results were
not positive. Follow-up periods of patients varied between
2 months and 21 years. The patient with mixed-type
lung involvement was given 6 postoperative courses of

Figure 4. A) Plasma cellular-type CD. Follicular hyperplasia
areas without hyaline vascular changes are observed under low
magnification (H&E, 100×). B) Massive plasma cell infiltration is
seen in the interfollicular area under high magnification (H&E,
400×).

rituximab treatment. This patient was followed with no
problems for 1 year. The patient who was diagnosed via
biopsy was given corticosteroid treatment by the medical
oncology clinic, but this treatment was not effective and
chemotherapy was initiated at postoperative month 6.
One of the patients who underwent R2 resection received
postoperative radiotherapy; this patient was followed for
4 months after surgery without any recurrence. A second
patient was followed by medical oncology without any
treatment. Three patients were lost to follow-up. Other
patients were followed with no problems.

Figure 3. Hyaline vascular-type CD; the germinal center is seen
with well-developed hyaline vascular structures (H&E, 400×).

4. Discussion
CD is angiofollicular lymph node hyperplasia caused by the
abnormal proliferation of plasma cells and B lymphocytes
in lymphoid tissues, and it is a rare lymphoproliferative
disorder (6). Clinically, there are localized types, in which
only a group of lymph nodes are involved, and a mixed type,
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involving 2 or more lymph nodes. Histopathologically,
there are hyaline vascular, plasma cellular, and mixed
types (1). According to the histopathogenetic classification
preferred in recent pathological publications, the
categories are hyaline vascular CD, plasma cellular CD,
HHV-8-associated CD, and multicentric CD not otherwise
specified (7).
The precise etiology of CD is unknown. However,
the high incidence of prior infection by opportunistic
HHV-8 in immunosuppressed patients detected with CD,
particularly in recent years, suggested the hypothesis that
viral interleukin-6 secreted by this virus might have a role
in its etiology (1,5). HHV-8-associated CD is generally
multicentric and has the risk of large B cell lymphoma
progression. It was reported that patients with human
immunodeficiency virus (HIV)-positive CD are always
infected with HHV-8 (8). Danon et al. reported that the
hyaline vascular type is composed of antigen-secreting
lymph nodes consisting of plasmacytoid monocytes, while
the plasma cell type might develop secondary to chronic
infections. However, no bacteria or other organisms were
isolated (9). In our study, HHV-8 DNA was analyzed in 3
patients: 2 with plasma cell CD and 1 with mixed-type CD.
None of the results were positive.
CD is more common in males (66%). The disease is
very rare in children; the hyaline vascular type is mostly
seen in the third and fourth decades, and the plasma
cellular type in the sixth decade (10). Our series did not
include pediatric patients. Patients ranged from 20 to 57
years of age. The average age of patients with the hyaline
vascular type was 38.9 years, and those with the plasma
cell type were 53 on average. The patient with mixed-type
multicentric involvement was 33 years old.
Approximately 90% of patients have hyaline
vascular CD and 90% are localized types. Rarely, cases
can be multicentric or aggressive (5). Although it is
asymptomatic, symptoms such as pain due to pressure,
coughing, shortness of breath, dysphagia, or stridor
occasionally develop (6). Plasma cell CD accounts for
less than 10% of cases. Although it is mostly observed
in multicentric form, prior studies have reported that it
was localized in 9%–24% of cases. In plasma cellular CD,
systemic symptoms and organomegaly associated with
interleukin-6 levels are more prevalent. Fever, night sweats,
weakness, loss of weight, anemia, thrombocytopenia,
hypergammaglobulinemia, and splenomegaly might
develop (5–7). HHV-8-related CD is a plasmablastic
variant of CD and continues to have a poor prognosis. It
generally appears in immune-suppressed and HIV-positive
patients, and lymphadenopathy, structural symptoms, and
hematologic and/or immunologic disorders often develop
(5). Our patient group was diagnosed with 84.2% hyaline
vascular, 10.5% plasma cellular, and 5.2% mixed-type CD.
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The lesions were multicentric in 2 patients and localized in
the others. All hyaline vascular types were of the localized
form. However, 1 of the plasma cellular type patients had
the localized form. One of the with multicentric localization
patients had the plasma cellular type while the other had
the mixed type. The most common symptom was chest
pain. As a systemic symptom, loss of weight was observed
in 2 patients with the multicentric mixed-type CD and the
hyaline vascular-type CD neighboring the esophagus.
It is difficult to diagnose CD, particularly in
asymptomatic patients. In radiological terms, typical
thoracic CD is generally observed in the mediastinal and
hilar regions, and in the form of a round solitary mass.
Mediastinal CD might be confused with thymoma,
lymphoma, sarcoma, hemangiopericytoma, or neurogenic
tumors. Hilar CD can be confused with lung cancer.
It is rarely located in pleural, pericardial, intercostal,
and intrapulmonary areas (5,10,11). Thorax CT scans
identified 3 presentations for the localized form of the
disease: solitary noninvasive masses were most prevalent
(50%), followed by infiltrative masses accompanied by
lymphadenopathy (40%) and lymphadenopathy with
no masses (10%). Homogeneous intensive contrast
involvement and hypervascular lesions are characteristic.
It was reported that calcification might be observed in
5%–10% of patients. On the other hand, multicentric
lesions can typically be observed in the form of bilateral
hilar and mediastinal lymphadenopathy, centrilobular
nodular opacity, and rarely ground glass, consolidation,
and bronchiectasis (10,12). The value of PET in diagnosis
is disputed, as it is not able to distinguish between
malignant disease and CD. However, it is beneficial to
show pathological involvement for a surgical approach and
in terms of whole-body scans (13). In our study, in terms
of tomography, lesions were most commonly mediastinal
and then hilar. Only 1 patient had bilateral lung lesions
and mediastinal lymphadenopathy. However, in the
postoperative period, some mediastinal and hilar lesions
were found in intrapulmonary (n = 2), intercostal (n = 2),
and interlobar (n = 2) locations.
In
patients
radiologically
diagnosed
with
hypervascular lesions, if surgery is decided upon,
preoperative embolization is recommended to lower the
risk of excessive bleeding (6,14). In our study, none of the
patients diagnosed with hypervascular lesions underwent
preoperative embolization. One patient experienced
excessive bleeding.
As in our study, since CD cannot be distinguished from
benign and malignant lesions, generally no preoperative
diagnosis is reached. An accepted approach for both
diagnostic and therapeutic reasons is surgical excision of
these lesions (15). The patients who underwent surgical
excision showed that surgery is almost always curative for
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either the hyaline vascular type or plasma cell localized CD
(8,10,16). Due to the invasive nature of lymphadenopathy
in multicentric diseases, complete surgical excision is
rarely possible (17). While surgical approaches typically
involve posterolateral thoracotomy, the literature contains
a limited body of research on video-assisted thoracoscopic
resection (8). The mode of surgical approach in our study
mostly involved standard thoracotomy (78%) and videoassisted thoracoscopy (15%). Mass excision was performed
in all but 2 patients. Curative resection was also achieved
in all but 2 localized cases.
Surgery provides excellent prognosis for the localized
form of the hyaline vascular type of CD. Radiotherapy
is recommended in localized patients who cannot be
resected or for whom complete resection cannot be
applied. Response to radiotherapy was reported as 72%
(18). In multicentric or aggressive forms, steroids, and/
or systemic chemotherapy, and in final stages rituximab,
are recommended when necessary (19). Plasma cellular
CD has a worse prognosis than hyaline vascular CD and
a better prognosis than HHV-8-related CD. Single or
combined chemotherapy, immune modulators (such as
interferon alpha and thalidomide), monoclonal antibodies
(such as anti-interleukin-6 and anti-CD20), and antiviral
drugs are used to treat the multicentric form of CD (5,10).
In our study, 1 of the 2 patients who underwent localized
R2 resections was given postoperative radiotherapy. This
patient had no recurrence 4 years postoperatively. The
other patient has had no postoperative problems, either.
Patients with multicentric forms of the disease had
different interventions: the 1 who had mixed-type CD and

received postoperative chemotherapy was followed for 1
year postoperatively with no problems. The patient with
plasma cellular CD first started corticosteroid treatment;
however, since the lesion did not shrink, the patient was
scheduled for chemotherapy at postoperative month 6.
Clinically, the potential for malignancy of local forms
is rare and 5-year life expectancy was reported to be 100%.
Long term follow-up is not recommended. However,
long-term follow-up is recommended for patients with
multicentric CD due to their increased risk for developing
multiple myeloma, B cell lymphoma, Hodgkin lymphoma,
or Kaposi sarcoma. Median survival rate of patients with
multicentric CD is 29 months; mortality was reported as
26% within 1 year of diagnosis (4,6,8,10). Two patients with
multicentric-type CD in the present study were followed
during the first year and the sixth month, respectively,
without any problems.
In conclusion, CD is a rare lymphoproliferative disease
that can affect every part of the thorax, most commonly
the mediastinum and hilum. Preoperative diagnosis is
difficult, and lesions can serve as a great mimic. Surgical
excision is an acceptable approach, both for diagnosis
and treatment. Aggressive forms with a multicentric
manifestation may occur with plasma cellular CD but are
uncommon with hyaline vascular CD. Complete excision
is curative in the local form of CD. However, due to local
invasion and hypervascularization, complete excision
might not always be achieved. Multimodal treatment
including chemotherapy is used for patients with the
multicentric form of the disease and close follow-up of
patients is recommended.
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